Second-line treatment options for hepatocellular carcinoma: current state and challenges for the future.
Le LiHao-Tian LiuYu-Xian TengZhu-Jian DengGuan-Lan ZhangJia-Yong SuLiang MaJian-Hong ZhongPublished in: Expert opinion on investigational drugs (2022)
There is no standard second-line treatment, especially for the case of sequential treatment after atezolizumab plus bevacizumab (atezo+bev) and further studies focused on sequential treatment are warranted in this setting. The design of clinical trials, different etiologies, and complications or quality of life (QoL) are interesting issues in the second-line setting.